FDA Form 483

Regulatory Event

FDA investigator Sangeeta M. Khurana of the Dallas District Office closed an eleven-day inspection of Turbare Manufacturing’s 503B outsourcing facility in Conway, Arkansas on May 7, 2026, documenting four observations spanning quality unit oversight, environmental and personnel monitoring, and batch investigation adequacy. The Form 483, issued to CEO Laura Martin, records what investigators observed during the inspection — it is not a finding that Turbare violated any regulation, and the company has 15 business days to respond before FDA’s Center for Drug Evaluation and Research decides whether the response is sufficient. What sharpens the read on this inspection is the site’s recent history: FDA’s FOIA Electronic Reading Room documents a prior 483 issued at this same facility on January 24, 2025 — centered on failure to investigate apparent Acceptable Quality Level (AQL) failures on repackaged Avastin lots — and Observation 4 of this new 483, covering an almost identical batch-investigation gap, is explicitly marked by the investigator as “a repeat observation.”

Observation 1, cited under 21 CFR 211.22(d) — the requirement that quality unit responsibilities and procedures be followed — is structured as a quality-unit indictment that organizes the rest of the document: the 483 states plainly that Turbare’s Quality Unit failed to ensure timely corrective action on a recurring equipment issue, failed to conduct adequate root-cause analysis on ongoing environmental and personnel monitoring excursions, failed to perform effectiveness checks on the corrective actions it did implement, failed to investigate visual-inspection failures before advancing lots to secondary review, and failed to evaluate airflow patterns in biological safety cabinets under actual operating conditions. Each of those four sub-findings is not a standalone technicality — it is the thread connecting Observations 2 through 4. When FDA frames a 483 this way, it is signaling that the individual findings are symptoms of one underlying condition: a quality unit that identifies problems but does not close the loop on whether the fix actually worked.

What the Record Documents

The environmental monitoring record substantiates that framing, and the underlying condition — procedures to prevent microbiological contamination of drug products purporting to be sterile were not followed — is cited under 21 CFR 211.113(b). Between July 2025 and April 2026, Turbare documented twenty-two separate fungal contamination excursions across ISO Class 7 and ISO Class 8 rooms directly adjacent to ISO Class 5 primary engineering controls — the classified space that supports aseptic compounding. More than sixteen distinct fungal species were recovered over that ten-month span, including Stachybotrys chlorohalonata, which the investigator specifically noted “may be toxigenic.” Corrective actions were not absent — Turbare revised its gowning and handwashing SOP, retrained personnel, and introduced a sporicidal agent to its material sanitization process — but fungal recoveries continued to recur through the month of the inspection itself, with five investigations still open and four consecutive fungal events documented in a single ISO 8 room within a twelve-day window in late March and early April. FDA’s Aseptic Processing Guidance treats a stable, low-bioburden environmental monitoring trend as the primary evidence that a facility’s contamination controls are actually functioning; a ten-month pattern of recurring fungal excursions despite repeated interventions is close to the opposite of that evidence, and it is why the 483 characterizes this as posing “a significant risk to the sterility of compounded drug products” rather than an isolated exceedance.

A second thread in Observation 2 concerns dynamic smoke studies — the qualification exercise that demonstrates unidirectional airflow actually protects the ISO 5 critical zone once real components, containers, and interventions are introduced, not just under empty, static conditions. The 483 documents that Turbare had not performed dynamic smoke studies since February 2024 on certain biological safety cabinets, and that at least 41 lots — including Avastin and vancomycin — were compounded in cabinets whose dynamic airflow qualification had not been refreshed in over two years. A static smoke study alone cannot establish first-air integrity under production conditions; without a current dynamic study, every environmental monitoring result collected from that hood during that window rests on an unverified assumption about airflow protection, which compounds the significance of the fungal recoveries described above.

Technical and Quality Context

Observation 3, cited under 21 CFR 211.28 for personnel hygiene, turns to personnel monitoring, documenting eleven contamination excursions between April 2025 and February 2026 involving gowning and fingertip samples across ISO 5, 7, and 8 areas. Several recoveries involved objectionable gram-negative organisms — Proteus species, Methylobacterium brachiatum, Moraxella osloensis — that are not part of normal skin flora and indicate a gowning or material-transfer control failure rather than routine background flora. Multiple operators appeared in more than one investigation with the same assigned root cause, which is itself evidence that retraining, as implemented, was not durably effective.

Observation 4, cited under 21 CFR 211.192 — the requirement to thoroughly review any unexplained discrepancy or batch failure to meet specifications — is the one FDA explicitly flags as a repeat: a review of ophthalmic lot visual inspection records identified forty-four lots that failed primary visual inspection or primary AQL testing and proceeded directly to secondary inspection — in two cases advancing further to tertiary inspection after a second failure — without a documented root-cause investigation in a single instance. Forty-four lots, zero documented investigations, is not an ambiguous finding; it is a quality system that treats a failed inspection stage as something to be worked around rather than understood. That this observation maps onto the same batch-investigation-adequacy gap FDA cited fifteen months earlier, in the January 2025 483, is the detail that should concern anyone assessing this site’s trajectory. A repeat citation of the same underlying control gap, on a different product line, at the next inspection, is one of FDA’s clearest signals that a facility’s Corrective and Preventive Action (CAPA) program is not producing durable change — and it is the type of pattern that most reliably escalates to a Warning Letter if it appears again at the next inspection.

Decision Relevance

Other 503B outsourcing facilities and sterile compounders should treat this 483 as a prompt to check three things independently of their own audit cycle: whether growth promotion testing is being used to justify returning incubators or storage equipment to service after an environmental excursion, when growth promotion testing under controlled inoculum conditions does not represent the stressed, low-count organisms recovered by passive air sampling in real use; whether dynamic smoke studies are refreshed on a defined schedule tied to product mix and fill volume, not treated as a one-time qualification; and whether every lot that fails a primary visual inspection or AQL stage triggers a documented investigation before it is permitted to advance to secondary or tertiary review, regardless of whether the lot ultimately passes.

XGene Consulting helps 503B outsourcing facilities and sterile manufacturers rebuild environmental monitoring investigation programs, requalify aseptic processing equipment after smoke-study gaps are identified, and design CAPA effectiveness-check processes that can demonstrate — with evidence, not just a closed ticket — that a corrective action actually changed practice on the floor. If your site has an observation that has recurred across two inspection cycles, the question worth asking now is not whether the last CAPA was closed, but whether it was ever truly effective.